Yahoo Web Search

Search results

1. • Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...

     Benzinga· 13 hours ago

     Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly

2. • 

     Chicago nurse is finally free of COVID-19-related PTSD and depression after electrical brain tapping...

     Fox News· 5 days ago

     A Chicago nurse has been liberated from her own mind, thanks to a brain-tapping technology called...

3. • The benefits of magnesium for healthy, restful sleep

     Nutraingredients.com· 23 hours ago

     Sleep is commonly defined as a periodic suspension of the state of consciousness during which the body recovers energy. Adults should regularly sleep seven or more hours per night to promote ...

4. • Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

     Benzinga· 13 hours ago

     NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive

5. • 

     Asthma, COPD often not diagnosed, study indicates

     United Press International via Yahoo News· 2 days ago

     Finding and treating people with undiagnosed asthma or chronic obstructive pulmonary disease improved their health and led to fewer appointments for...

6. • 

     5 Things to Know: COVID-19 Vaccines for Immunocompromised People

     Medscape· 5 days ago

     CDC experts share what clinicians should know about COVID-19 prevention in immunocompromised...

7. • TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...

     FOX 23 News Albany· 20 hours ago

     WASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...

8. • 

     Richard Feldman column: COVID is not gone; proceed with caution

     The Herald Bulletin· 7 days ago

     There’s an expression, “You may be done with COVID, but COVID isn’t done with you.” The situation...

9. • 

     HCC Screening of At-Risk Adults Improves Detection, Survival

     Medscape· 6 days ago

     Hepatocellular carcinoma screening was associated with earlier detection and improved survival, even...

10. • NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD

      WTNH-TV New Haven· 1 day ago

      Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive ...